Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.

Details

Serval ID
serval:BIB_543A8F0BDA2E
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.
Journal
Neuro-Oncology
Author(s)
Wasserfallen J.B., Ostermann S., Leyvraz S., Stupp R.
ISSN
1522-8517
Publication state
Published
Issued date
04/2005
Peer-reviewed
Oui
Volume
7
Number
2
Pages
189-195
Language
english
Notes
Publication types: Clinical Trial ; Journal Article
Abstract
Effectiveness and costs of care and treatment of recurrent malignant gliomas are largely unknown. In this study, 49 patients (32 males, 17 females; mean age, 49; age range, 23-79) were treated with temozolomide (TMZ) for recurrent or progressive malignant gliomas after standard radiation therapy. Cost assessment (payer's perspective) singled out treatment for first recurrence and all costs of care until death. We computed personnel costs as wages; drugs, imaging, and laboratory tests as prices; and hospitalizations as day rates. Patients were administered a median of five TMZ cycles at recurrence. Drug acquisition costs amounted to euro 2206 per cycle (76% of total costs). Seven patients showed no second recurrence (two are still alive), 16 received no further chemotherapy and died after 3.9 months, and 26 received second-line chemotherapy. After the second progression, median survival was 4.0 months (95% confidence interval, 1.8-6.1). Overall monthly costs of care varied between euro 2450 and euro 3242 among the different groups, and median cost-effectiveness and cost utility ranged from euro 28,817 to euro 38,450 and from euro 41,167 to euro 53,369 per life of year and per quality-adjusted life-year gained, respectively. We conclude that despite high TMZ drug acquisition costs, care of recurrent malignant gliomas is comparable to other accepted therapies.
Keywords
Adult, Aged, Antineoplastic Agents, Alkylating/economics, Antineoplastic Agents, Alkylating/therapeutic use, Brain Neoplasms/drug therapy, Brain Neoplasms/economics, Cost of Illness, Cost-Benefit Analysis, Dacarbazine/analogs &amp, derivatives, Dacarbazine/economics, Female, Glioma/drug therapy, Glioma/economics, Humans, Male, Middle Aged, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, Local/economics, Survival Analysis
Pubmed
Web of science
Open Access
Yes
Create date
28/01/2008 8:39
Last modification date
20/08/2019 14:09
Usage data